Myriad Genetics (NASDAQ: MYGN) had its price target decreased by Credit Suisse to $28.00 in a research report sent to investors on Monday morning. The firm currently has a neutral rating on the stock.
Myriad Genetics opened at 25.03 on Monday. Myriad Genetics has a 52-week low of $22.02 and a 52-week high of $31.80. The stock’s 50-day moving average is currently $26.02. The company has a market cap of $2.017 billion and a price-to-earnings ratio of 17.16.
A number of other firms have also recently commented on MYGN. Analysts at Jefferies Group cut their price target on shares of Myriad Genetics from $33.00 to $31.00 in a research note to investors on Monday. They now have a buy rating on the stock. Separately, analysts at Zacks reiterated an outperform rating on shares of Myriad Genetics in a research note to investors on Tuesday, February 12th. They now have a $30.00 price target on the stock. Finally, analysts at Cowen reiterated an outperform rating on shares of Myriad Genetics in a research note to investors on Wednesday, February 6th.
Nine analysts have rated the stock with a buy rating, eight have issued a hold rating, and one has issued a sell rating to the company’s stock. The company presently has an average rating of overweight and a consensus price target of $30.00.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
